ReShape Lifesciences shareholders approve 2022 equity plan, reverse split, authorized share increase

The Company’s stockholders approved an amendment to Article IV, Section 1 of the Certificate of Incorporation to increase the number of shares of common stock authorized for issuance to 300,000,000 shares, as set forth below. Votes For Votes Against Abstentions 72,167,316 ​ 17,231,487 ​ 29,146

The Company’s stockholders authorized the Board, in its discretion but in no event later than December 14, 2023, which is one year after the date of the Annual Meeting, to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1-for-30 to 1-for-100, such ratio to be determined by the Board and included in a public announcement, as set forth below. Votes For Votes Against Abstentions 73,383,162 ​ 13,008,564 ​ 36,223

The Company’s stockholders elected Paul F. Hickey as a Class III director to hold office until the 2025 annual meeting of stockholders or until his successor is elected and qualified, or, if sooner, until his death, resignation or removal, as set forth below. Votes For Votes Withheld Broker Non-Votes 5,366,444 ​ 580,976 ​ 8,480,529

The Company’s stockholders approved the ReShape Lifesciences Inc. 2022 Equity Incentive Plan, as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 3,721,022 ​ 2,142,351 ​ 84,047 ​ 8,480,529

The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, as set forth below. Votes For Votes Against Abstentions 13,866,558 ​ 417,065 ​ 144,326

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as set forth below. Votes For Votes Against Abstentions Broker Non-Votes 4,054,583 ​ 1,837,687 ​ 55,150 ​ 8,480,529